micrornas!as! Biomarkers! Landscape!

Size: px
Start display at page:

Download "micrornas!as! Biomarkers! Landscape!"

Transcription

1 GENReports: Market & Tech Analysis micrornas!as! Biomarkers! Landscape! > Enal Razvi, Ph.D. Managing Director Select Biosciences, Inc.

2 Topic Introduction and Scope! The,focus,of,this,GEN,Market,&,Tech,Analysis,Report,is,to,provide, an, update, on, the, progress, of, micrornas, as, potenbal, biomarkers, for,disease,! This,is,important,given,the,fact,that,microRNA,expression,paEerns, (signatures), represent, the, in# vivo, status, in, physiology, or, disease, and, have, been, shown, to, have, veryhspecific, Bssue, expression, paeerns,! In, this, report, we, document, some, of, the, qualitabve, and, quanbtabve, metrics, as, we, seek, to, map, the, microrna, landscape, vishàhvis,their,ublity,as,biomarkers,! The,quanBtaBve,data,in,this,report,were,updated,in,October,2014, therefore,represent,a,very,uphtohdate,market,picture, microrna,progression,from,research,towards,the,clinic,

3 !35,000!!!30,000!!!25,000!!!20,000!!!15,000!!! Sustained,YearHonHYear,Growth,of,microRNA,Sequence,Content,! Ordinate:,microRNA,Curated,Sequences,in,the,Database,! Abscissa:,Release,Date,and,miRBase,Version,! mirbase,is,hosted,and,maintained,in,the,faculty,of,life,sciences, at,the,university,of,manchester,,uk,! Numbers,illustrate,the,total,number,of,entries,in,the,registry,at, given,bme,intervals,! This,figure,provides,a,perspecBve,on,the,growth,of,the,microRNA, content,available,for,harvest,of,biomarker,candidates,!10,000!!!5,000!!!c!!!! Release Date 12/1/02! 1/1/03! 4/1/03! 5/1/03! 7/1/03! 7/1/03! 9/1/03! 11/1/03! 1/1/04! 4/1/04! 7/1/04! 9/1/04! 12/1/04! 4/1/05! 6/1/05! 10/1/05! mirbase 1.0! 1.1! 1.2! 1.3! 1.4! 2.0! 2.1! 2.2! 3.0! 3.1! 4.0! 5.0! 5.1! 6.0! 7.0! 7.1! 8.0! 8.1! 8.2! 9.0! 9.1! 9.2!10.0!10.1!11.0!12.0!13.0! 14! 15! 16! 17! 18! 19! 20! 21! Version 2/1/06! 5/1/06! 7/1/06! 10/1/06! 2/1/07! 5/1/07! 8/1/07! 12/1/07! 4/1/08! 9/1/08! 3/1/09! 9/1/09! 4/1/10! 8/1/10! 4/1/11! 11/1/11! 8/1/12! 6/1/13! 6/1/14!

4 450 microrna,publicabons,analysis, Cancer,is,the,Key,Driver,of,the,microRNA,Space:, Bars,in,Yellow,Represent,Large,Swaths,of,PublicaBons, which,segregate,within,the,various,cancer,spaces, This,figure,provides,evidence,that,the,researchers, in,the,microrna,space,are,primarily,cancerhfocused,,, Number of Publications ADENOCARCINOMA B-CELL LYMPHOMA BLADDER CANCER BREAST CANCER BURKITT LYMPHOMA CERVICAL CANCER CHRONIC LYMPHOCYTIC COLON CANCER COLORECTAL CANCER EM_TRANSITION HUMAN LYMPHOMA GASTRIC CANCER GLIOBLASTOMA HCC HEPATIC CANCER HEPATOCELLULAR HODGINS LYMPHOMA LEUKEMIA LUNG CANCER METASTASIS MYELODYSPLASTIC MYELOID LEUKEMIA NON-SMALL CELL LUNG OVARIAN CANCER PANCREATIC CANCER PROSTATE CANCER SQUAMOUS CELL THYROID CANCER ALZHEIMERS DISEASE ANGIOGENESIS DIABETES INFLAMMATION OBESITY SCHIZOPHRENIA CARDIOVASCULAR MYOCARDIAL DISEASE MYOCARDIAL NEURODEGENERATIVE NEUROLOGICAL DISEASE NEURONAL PARKINSONS DISEASE BONE MARROW HEMATOPOIESIS HEMATOPOIETIC HEPATITIS C VIRUS STEM CELLS TUMOR SUPPRESSOR

5 mirc1! mirc101! mirc104! mirc106a! mirc10b! mirc112! mirc1206! mirc124! mirc124ca3! mirc125a! mirc127! mirc128b! mirc130! mirc130c! mirc133! mirc134! mirc135b! mirc138! mirc13b! mirc141! mirc144! mirc146a! mirc148! mirc149! mirc151! mirc154! mirc15b! mirc166! mirc16a! mirc17c92!cluster! mirc181a! mirc181d! mirc184! mirc187! mirc19! mirc192! mirc193c! mirc196! mirc196b! mirc1997! mirc19a! mirc2! mirc200a! mirc203! mirc206! mirc20b! mirc212! mirc216! mirc219! mirc221! mirc224! mirc23b! mirc25! mirc26b! mirc277! mirc27a! mirc29! mirc29a! mirc2a! mirc301! mirc302b! mirc303! mirc30b! mirc31! mirc32! mirc323! mirc33! mirc335! mirc339! mirc346! mirc34c! mirc368! mirc372! mirc376! mirc379! mirc39! mirc410! mirc423! mirc430! mirc48! mirc493! mirc503! mirc520c! mirc551b! mirc615! mirc663! mirc691! mirc720! mirc8! mirc9! mirc93! mirc98! mirclet7! Profiling!Expression!of!this!miR! UpCRegulaQng!this!miR! DownCRegulaQng!this!miR!! Data,Based,on,Primary,Survey,of,microRNA,Researchers,! Presents,the, Penetrance,of,Some,but,not,all,microRNAs,in,Research,Currently,! Similar,to,microRNAHfocused,PublicaBons,,Penetrance,of,microRNAHfocused,Researchers,visHàHvis,Specific,microRNAs,is,Yet,Another, Metric,to,Characterize,the,Granularity,of,the,microRNA,Space,Illustrated,here,! The,height,of,each,bar,is,proporBonal,to,the,penetrance,of,that,parBcular,microRNA,into,the,research,community, Study,of,microRNA,Content,by,Researchers,Currently,

6 Selected,Tumor,Classes,Showing,Altered,Expression,[UpregulaBon,,DownregulaBon],of, Various,MicroRNAs, Lung Breast Tissue/Tumor Type Increased Expression Decreased Expression Glioblastoma Chronic Lymphocytic Leukemia (CLL) Lymphoma Colorectal Thyroid Hepatocellular mir cluster mir-17-5p mir-21 mir-29b-2 mir-221 mir-21 mir-155 mir cluster mir-10a mir cluster mir-20a mir-24-1 mir-29b-2 mir-31 mir-221, mir-222 mir-146, mir-181b, mir-197, mir-346 mir-18 mir-224 let-7 family mir-125b, mir145, mir-10b, mir-155, mir-17-5p, mir-27b mir-181a, mir-181b, mir-181c mir-15 mir-16 mir-15a mir-143 mir-145 let-7 mir-199a, mir-195, mir-200a, mir-125a

7 Selected,microRNAs/microRNA,Signatures,in,GI,Tract,Tumors,and, their,potenbal,diagnosbc,significance, microrna, Signature, Tumor,Type, Clinical,Value, Significance, Proposed,Role, mirc15b! DownregulaQon! Gastric!cancer! Prognosis!! Predictor!of!Drug! Resistance! mirc16! DownregulaQon! Gastric!cancer! Prognosis!! Predictor!of!Drug! Resistance! mirc20b! UpregulaQon! Gastric!cancer! Prognosis!! Level!inversely! correlated!with! survival! oncomir! mirc21! UpregulaQon! Gastric!cancer,!Hepatocellular! carcinoma,!esophageal! squamous!cell!carcinoma,! colorectal!cancer,!pancreaqc! cancer! Diagnosis!! Common!Cancer! Biomarker!! Local!Invasion!! Tumor!Grade! oncomir! mirc27a! UpregulaQon! Gastric!cancer,!Esophageal! squamous!cell!carcinoma! Prognosis!! MetastaQc!PotenQal! mirc106a! UpregulaQon! Gastric!cancer! Prognosis!! Tumor!stage! oncomir! mirc122! DownregulaQon! Hepatocellular!carcinoma! Diagnosis!! Tumor!Specific! Tumor!Suppressor! mirc125b! DownregulaQon! Hepatocellular!carcinoma,! Esophageal!squamous!cell! carcinoma! Prognosis!! Good!Survival! Tumor!Suppressor! mirc133b! DownregulaQon! Colorectal!cancer! Diagnosis!! Tumor!vs!Normal! Tumor!Suppressor! mirc150! UpregulaQon! Gastric!cancer! Prognosis!! Level!inversely! oncomir! correlated!with! survival!

8 MicroRNAs,Associated,with,Vascular,Diseases,, InflammaBon,,and,Angiogenesis, DownHRegulated, mirc16,!mirc17c5p,!mirc19b,!mirc22,! mirc23b,!mirc24,!mirc27a,!mirc30ac5p,! mirc30b,!mirc30c,!mirc30ec5p,!mirc107,! mirc126,!mirc130b,!mirc135a,!mirc136,! mirc148a,!mirc150,!mirc182,!mirc186,! mirc192,!mirc199a*,!mirc218,!mirc299c5p,! mirc302b*,!mirc302c*,!mirc325,!mirc339,! mirc342,!mirc452,!mirc452*,!mirc494,! mirc495,!mirc497,!mirc499,!mirc507,! mirc512c5p,!mirc515c5p,!mirc520d*,! mirc520h,!mirc520,!mirc523,!mirc526b,! mirc526b*! UpHRegulated, mirc1,!mirc7a,!mirc7b,!mirc7c,!mirc7d,!mirc7e,! mirc7f,!mirc10b,!mirc17c3p,!mirc21,!mirc23,! mirc24,!mirc26a,!mirc28,!mirc29a,!mirc29b,! mirc29c,!mirc32,!mirc34b,!mirc98,!mirc106b,! mirc125a,!mirc125b,!mirc126*,!mirc129,! mirc129c3p,!mirc130a,!mirc132,!mirc195,! mirc196a,!mirc199a,!mirc199b,!mirc200c,! mirc204,!mirc205,!mirc208,!mirc210,!mirc211,! mirc212,!mirc213,!mirc214,!mirc215,!mirc292c3p,! mirc294,!mirc295,!mirc296,!mirc297,!mirc300,! mirc302a,!mirc320,!mirc322,!mirc330,!mirc331,! mirc333,!mirc340,!mirc341,!mirc343,!mirc365,! mirc367,!mirc372,!mirc373,!mirc377,!mirc381,! mirc382,!mirc423,!mirc424,!mirc429,!mirc432,! mirc500,!mirc520c,!mirc525*! Its,Not,Just,in,Cancer,Where,microRNA,AssociaBons,with,Disease, Have,been,Documented,,

9 Acute myeloid Leukemia (AML) Acute myocardial infarction (AMI) Selected,Plasma,microRNAs,as,Candidate, Biomarkers,in,Various,Disease,Classes Disease Change Biomarker microrna Breast cancer Colorectal cancer Non-small cell lung cancer (NSCLC) Sepsis Type 2 diabetes Pregnancy Down Up Up Up Down Up Down Down Down Up mir-92a mir-1, mir-133, mir-208a, mir-499 let-7a, mir-195 mir-17-3p, mir-135b, mir-222, mir-29a, mir-92a, mir-95 mir-25 mir-23a, mir-25, mir-27a, mir-125b, mir-128b, mir-146a, mir-150, mir-152, mir-223,mir-20b, mir-30e-3p, let-7f mir-146a, mir-223 mir-126 mir-141, mir-149, mir-299-5p, mir-135b Note,the,Disease,Classes,and,the,Fact,that,microRNAs,can,be,Harvested,from,Plasma,opens,up, the,potenbal,for,biofluidhbased,biopsies,for,disease,

10 NIH Funded microrna biomarker Projects 16! 14! 12! 10! 14!! This!Figure!Presents!the!Number,of,Funded,Grants/, Projects!by!the!Various!NIH!Funding!Agencies!! The!focus!of!these!projects!is!on!microRNAs!with! some!aspect!of!the!project!focusing!on! microrna! Biomarkers!! Total!Number!of!Grants/Projects!=!41! 8! 6! 4! 4! 4! 3! 3! 2! 2! 2! 2! 1! 1! 1! 1! 1! 2! 0! NCI! NIA! NCATS! NIAAA! NHLBI! NIDCR! NIGMS! NIDDK! NIAID! NIMH! NIAMS! NEI! NICHD! NIEHS! Data!Source:!US!Dept.!of!Health!and!Human!Services!

11 NIH Funded microrna biomarker Projects $7,000,000! $6,000,000! $5,722,649! $5,000,000!! This!Figure!Presents!the!Dollar,Value,of,Grants/, Funded,Projects!by!the!Various!NIH!Funding!Agencies!! The!focus!of!these!projects!is!on!microRNAs!with! some!aspect!of!the!project!focusing!on! microrna! Biomarkers!! Total!Value!of!these!Grants/Projects!=!$20.46!Million! $4,481,087! $4,000,000! $3,000,000! $2,688,794! $2,136,200! $2,000,000! $1,487,191! $1,000,000! $491,528! $578,131! $671,311! $491,903! $421,414! $363,901!$382,085! $240,000! $307,469! $0! NCI! NIA! NCATS! NIAAA! NHLBI! NIDCR! NIGMS! NIDDK! NIAID! NIMH! NIAMS! NEI! NICHD! NIEHS! Data!Source:!US!Dept.!of!Health!and!Human!Services!

12 In Summary! In! this! report! we! have! sought! to! present! the! landscape! of! microrna! research! as! it! relates! to! the! development! of! micrornacbased! biomarkers!for!various!disease!classes!! Clearly,! the! research! world! of! micrornas! is! driven! by! cancer! primarily! (but!this!is!now!becoming!morecinclusive!of!other!disease!classes!such! as!cardiovascular!disease!and!cns!disease)!! We! further! present! selected! associaqons! of! microrna! signatures! with! various! disease! classes this! snapshot! is! meant! to! illustrate! the! exquisite!specificity!that!such!a!signature!affords!and!the!challenge!is!to! idenqfy!and!validate!such!signatures!across!disease!classes!! Eventually,!these!signatures!can!be!developed!into!diagnosQcs!! Importantly,!the!fact!that!microRNAs!can!be!harvested!from!biological!fluids!enables! the! development! of! biofluid! biopsies! wherein! circulaqng! biomarkers! such! as! micrornas!can!be!captured!and!analyzed!ex!vivo!! The!NIH!is!funding!to!the!tune!of!US$20!Million!research!efforts!some! parts! of! which! impinge! on! microrna! biomarker! validaqon! and! development!

microrna Therapeutics Heading Towards the Clinic

microrna Therapeutics Heading Towards the Clinic GENReports: Market & Tech Analysis microrna Therapeutics Heading Towards the Clinic > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us Topic Introduction and Scope

More information

Characteristics of Cancer Stem Cells (CSCs)

Characteristics of Cancer Stem Cells (CSCs) GENReports: Market & Tech Analysis Characteristics of Cancer Stem Cells (CSCs) > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director Select Biosciences, Inc. enal@selectbio.us! Topic,IntroducEon,and,Scope!

More information

NIDDK: Priorities and Perspectives. NIDDK: Support of Fatty Liver Disease Research. National Institutes of Health $30,142,653,000

NIDDK: Priorities and Perspectives. NIDDK: Support of Fatty Liver Disease Research. National Institutes of Health $30,142,653,000 NIDDK: Priorities and Perspectives Edward Doo Program Director Liver Diseases Research Branch, NIDDK National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health STOPNASH

More information

Thank You. Presented By. Title Sponsor. Venue Host

Thank You. Presented By. Title Sponsor. Venue Host Thank You Presented By Title Sponsor Venue Host NIDDK Research: Opportunities for Partnering Vladimir Knezevic, M.D. Senior Advisor for Commercial Evaluation, Technology Advancement Office, National Institute

More information

Planning, Priority Setting, and Budget Development for NIH AIDS Research

Planning, Priority Setting, and Budget Development for NIH AIDS Research Planning, Priority Setting, and Budget Development for NIH AIDS Research Robert W. Eisinger, Ph.D. Office of AIDS Research s of Health Focus of Presentation Overview of OAR Priority Setting Process Budget

More information

BD-STEP: Tackling Key Issues Across Cancer Research and Care

BD-STEP: Tackling Key Issues Across Cancer Research and Care BD-STEP: Tackling Key Issues Across Cancer Research and Care Michelle Berny-Lang, Ph.D. Program Director Center for Strategic Scientific Initiatives Office of the Director, National Cancer Institute BD-STEP

More information

President's FY 2009 Budget Request for R&D and Public Health Programs

President's FY 2009 Budget Request for R&D and Public Health Programs Request for R&D and Public Health Programs (in millions) : http://www.whitehouse.gov/omb/budget/fy2007/ FY Final Appropriations: http://thomas.loc.gov/home/approp/app08.html FY Levels based on Documents

More information

GENReports: Market & Tech Analysis

GENReports: Market & Tech Analysis GENReports: Market & Tech Analysis > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director Select Biosciences, Inc. enal@selectbio.us! The,focus,of,this,GEN,Market,&,Tech,Analysis,Report,is,to,frame,a,

More information

microrna Presented for: Presented by: Date:

microrna Presented for: Presented by: Date: microrna Presented for: Presented by: Date: 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions

More information

ADC Clinical Core Leaders meeting: Can we do more with biomarkers? Joseph Quinn, MD. April 16, 2016

ADC Clinical Core Leaders meeting: Can we do more with biomarkers? Joseph Quinn, MD. April 16, 2016 ADC Clinical Core Leaders meeting: Can we do more with biomarkers? Joseph Quinn, MD April 16, 2016 1 New initiatives with biomarkers of neurodegenerative disease: Extracellular micrornas as biomarkers

More information

America, Hershey, PA Australia, Melbourne, VIC Europe, Munich

America, Hershey, PA Australia, Melbourne, VIC Europe, Munich America, Hershey, PA Australia, Melbourne, VIC Europe, Munich info@vivopharm.com www.vivopharm.com Bladder MB-9-luc 2 Mouse urinary bladder carcinoma yes yes yes C57BL/6 2 Bone UMR-106 Rat osteosarcoma

More information

The NIH STTR Program

The NIH STTR Program The NIH STTR Program May 1, 2015 Matthew Portnoy, Ph.D. SBIR/STTR Program Coordinator, NIH 1 Topics Size of NIH/HHS program Set-asides & spending Research Institutions and Universities in STTR Discretionary

More information

FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center

FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center 1430 Tulane Ave., Box SL-68, New Orleans, LA 70112-2699 J. Bennett Johnston Building, Mezzanine (Floor 1A), Suite A102 (504) 988-6060, fax (504) 988-6077,

More information

Species Tumor Type Comment for in vivo work Lead Time for in vivo studies [weeks] MB-49-luc-2 Mouse urinary bladder carcinoma C57BL/6 2

Species Tumor Type Comment for in vivo work Lead Time for in vivo studies [weeks] MB-49-luc-2 Mouse urinary bladder carcinoma C57BL/6 2 America, Hershey, PA Australia, Melbourne, VIC Europe, Munich info@vivopharm.com www.vivopharm.com Tissue Bladder Species Tumor Type Comment for in vivo work Lead Time for in vivo studies [weeks] MB-49-luc-

More information

Healing After Plague: Lessons Applied. Emerging Concepts

Healing After Plague: Lessons Applied. Emerging Concepts Healing After Plague: Lessons Applied Emerging Concepts Recombination events in animal and human cells can generate families of infectious related gamma retroviruses Greatest concern is that they have

More information

GENReports: Market & Tech Analysis

GENReports: Market & Tech Analysis GENReports: Market & Tech Analysis > Gary Oosta, Ph.D. Biotechnology Analyst, Select Biosciences, Inc. > Enal Razvi, Ph.D. Managing Director Select Biosciences, Inc. enal@selectbio.us Twitter: @enalrazvi

More information

Research Training Opportunities at the National Institute on Aging

Research Training Opportunities at the National Institute on Aging Research Training Opportunities at the National Institute on Aging Arlene Jackson Jaron Lockett, Ph.D. NIA Intramural Scientific Recruiters NIA Recruitment 2010 National Institutes of Health (NIH) Mission:

More information

8/17/2011. FY 2010 President s Budget Request Total NIH Budget Authority $31.0 Billion

8/17/2011. FY 2010 President s Budget Request Total NIH Budget Authority $31.0 Billion NIH OD NCI NEI NHLBI NHGRI NIA NIAAA NIAID NIAMS NIBIB NICHD NIDCD NIDCR NIDDK NIDA NIEHS NIGMS NIMH NINDS NINR NLM CIT CSR FIC NCCAM NCMHD NCRR FY 2010 President s Budget Request Total NIH Budget Authority

More information

Advancing Therapeutic Development for Pain and Opioid Use Disorder through Public-Private Partnerships

Advancing Therapeutic Development for Pain and Opioid Use Disorder through Public-Private Partnerships The National Academies of SCIENCES ENGINEERING MEDICINE Advancing Therapeutic Development for Pain and Opioid Use Disorder through Public-Private Partnerships Leadership The NIH Pain Consortium Mission

More information

Lita M. Proctor, Ph.D. NHGRI/NIH. for NIH Human Microbiome Project. April 11, 2011 Health Disparities Summit

Lita M. Proctor, Ph.D. NHGRI/NIH. for NIH Human Microbiome Project. April 11, 2011 Health Disparities Summit Lita M. Proctor, Ph.D. NHGRI/NIH for NIH Human Microbiome Project April 11, 2011 Health Disparities Summit Today s talk What are microbes and why are they important? What is the human microbiome and why

More information

Fogarty Initiatives for Building Capacity in HIV/AIDS

Fogarty Initiatives for Building Capacity in HIV/AIDS Fogarty Initiatives for Building Capacity in HIV/AIDS April 13, 2010 Michael P. Johnson, M.D., M.P.H Deputy Director Fogarty International Center Global Health Transition in 21 st Century the unfinished

More information

The NIH SBIR/STTR Program & Universities

The NIH SBIR/STTR Program & Universities The NIH SBIR/STTR Program & Universities SBIR/STTR & Commercialization of University Innovations February 5, 2014 Matthew Portnoy, Ph.D. SBIR/STTR Program Coordinator, NIH 1 Topics Size of NIH/HHS program

More information

MicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL

MicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL MicroRNA expression profiling and functional analysis in prostate cancer Marco Folini s.c. Ricerca Traslazionale DOSL What are micrornas? For almost three decades, the alteration of protein-coding genes

More information

TUMOR M ARKERS MARKERS

TUMOR M ARKERS MARKERS TUMOR MARKERS M.Shekarabi IUMS Definition Many cancers are associated with the abnormal production of some molecules l which h can be measured in plasma. These molecules are known as tumor markers. A good

More information

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on

More information

Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group

Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group Introduction There are more than 200 different types of cancer. It is also referred to as malignancies,

More information

mirna Dr. S Hosseini-Asl

mirna Dr. S Hosseini-Asl mirna Dr. S Hosseini-Asl 1 2 MicroRNAs (mirnas) are small noncoding RNAs which enhance the cleavage or translational repression of specific mrna with recognition site(s) in the 3 - untranslated region

More information

Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths

Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths RSNA, 2016 10.1148/radiol.2016152472 Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths Observed/Expected No. of Deaths Observed/Expected

More information

Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017

Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017 Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017 Supplemental nation Status of Development Pipeline as of May 8, 2017. Main Status of Development Pipelines (Oncology) 1. Development Status

More information

2008 Oncology Pharmacy Preparatory Review Course Learning Objectives

2008 Oncology Pharmacy Preparatory Review Course Learning Objectives 2008 Oncology Pharmacy Preparatory Review Course Learning Objectives Session 1 Symptom Management, Part I, II & III Teresa A. Mays, Pharm D., BCOP Director, Investigational Drug Department San Antonio,

More information

About OMICS Group Conferences

About OMICS Group Conferences About OMICS Group OMICS Group International is an amalgamation of Open Access publications and worldwide international science conferences and events. Established in the year 2007 with the sole aim of

More information

Tumor Markers & Cytopathology

Tumor Markers & Cytopathology Tumor Markers & Cytopathology Objectives: After learning, student should be able to 1. Describe the basic concepts of tumor markers and Asst. Prof. Prasit Suwannalert, Ph.D. (Email: prasit.suw@mahidol.ac.th)

More information

FY 2008 Appropriations for R&D and Public Health Programs (in millions)

FY 2008 Appropriations for R&D and Public Health Programs (in millions) FY 2008 Appropriations for R&D and Public Health Programs (in millions) AGENCY PROGRAM FY 2008 Appropriations Status: http://thomas.loc.gov/home/approp/app08.html FY 2008 : http://www.whitehouse.gov/omb/budget/fy2007/

More information

Summary of Research and Writing Activities in Oncology

Summary of Research and Writing Activities in Oncology Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,

More information

Tumour Structure and Nomenclature. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge

Tumour Structure and Nomenclature. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge Tumour Structure and Nomenclature Paul Edwards Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge Malignant Metastasis Core idea of cancer Normal Cell Slightly

More information

Overview of the NIH. National Institutes of Health (NIH)

Overview of the NIH. National Institutes of Health (NIH) Overview of the National Institutes of Health (NIH) October 16, 2008 Craig Formby, Ph.D. Distinguished Graduate Research Professor Colleges of Arts & Sciences, Medicine, and Engineering Director, Office

More information

Asexual Reproduction & Cancer

Asexual Reproduction & Cancer Asexual Reproduction & Cancer Asexual Reproduction Only one individual needed No new genetic material added = organism clones itself Reproduction is fast and produces many individuals Gene pool is shallow

More information

Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group

Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group Introduction There are more than 200 different types of cancer. It is also referred to as malignancies,

More information

Human cell line list Production of Exosome Standards - Cell Lysates

Human cell line list Production of Exosome Standards - Cell Lysates Human cell line list 2016 - Production of Exosome Standards - Cell Lysates 380 peripheral blood leukemia, pre-b cell 1301 blood leukemia, acute lymphoblastic, T cell 5637 bladder carcinoma 8305C thyroid

More information

Oncology 101. Cancer Basics

Oncology 101. Cancer Basics Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases

More information

Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group

Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group Introduction There are more than 200 different types of cancer. It is also referred to as malignancies,

More information

List of Available TMAs in the PRN

List of Available TMAs in the PRN TMA RPCI_BrainCa01 RPCI_BrCa03 RPCI_BrCa04 RPCI_BrCa05 RPCI_BrCa0 RPCI_BrCa07 RPCI_BrCa08 RPCI_BrCa15 RPCI_BrCa1 RPCI_BrCa17 RPCI_BrCa18 RPCI_BrCa19 RPCI_BrCa20 RPCI_BrCa21 RPCI_BrCa24 RPCI_BrCa25 RPCI_BrCa2

More information

2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives

2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives 2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives Acute Leukemia/Tumor Lysis Syndrome John M. Valgus, Pharm.D., BCOP Hematology/Oncology Specialist University of North

More information

American Society of Clinical Oncology PATIENT EDUCATION MATERIALS CATALOG.

American Society of Clinical Oncology PATIENT EDUCATION MATERIALS CATALOG. American Society of Clinical Oncology PATIENT EDUCATION MATERIALS CATALOG www.cancer.net www.cancer.net Tell your patients about the ASCO doctor-approved PATIENT INFORMATION WEBSITE Cancer.Net brings the

More information

Composed of 27 Institutes and Centers.

Composed of 27 Institutes and Centers. October 7, 2009 John C. Higginbotham, PhD, MPH Associate Dean for Research & Health Policy Professor and Chair, Department of Community & Rural Medicine Director, Rural Health Institute for Clinical &

More information

Cancer Facts & Figures for African Americans

Cancer Facts & Figures for African Americans Cancer Facts & Figures for African Americans What is the Impact of Cancer on African Americans in Indiana? Table 12. Burden of Cancer among African Americans Indiana, 2004 2008 Average number of cases

More information

Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser

Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser Melissa S. Cline 1*, Brian Craft 1, Teresa Swatloski 1, Mary Goldman 1, Singer Ma 1, David Haussler 1, Jingchun Zhu 1 1 Center for Biomolecular

More information

OncoMir Library Cancer Type Target Gene

OncoMir Library Cancer Type Target Gene OncoMir Library Cancer Type Target Gene hsa-let-7a-1 Breast Cancer, Lung Cancer H RAS, HMGA2, CDK6, NRAS hsa-let-7a-2 Breast Cancer, Lung Cancer H RAS, HMGA2, CDK6, NRAS hsa-let-7a-3 Breast Cancer, Lung

More information

Personalized Medicine: Home Test Kit for Cancer

Personalized Medicine: Home Test Kit for Cancer Personalized Medicine: Home Test Kit for Cancer Joanne I. Yeh, Ph.D Associate Professor, Department of Structural Biology, University of Pittsburgh; Associate Professor, Department of Bioengineering, University

More information

Chapter 15: Non-Head and Neck Solid Tumors in Patients with Fanconi Anemia

Chapter 15: Non-Head and Neck Solid Tumors in Patients with Fanconi Anemia Chapter 15: Non-Head and Neck Solid Tumors in Patients with Fanconi Anemia Introduction Cancer is a major concern in FA patients. This chapter will describe the most common types of non-head and neck solid

More information

The Cancer Genome Atlas

The Cancer Genome Atlas The Cancer Genome Atlas July 14, 2011 Kenna M. Shaw, Ph.D. Deputy Director The Cancer Genome Atlas Program TCGA: Core Objectives Launched in 2006 as a pilot and expanded in 2009, the goals of TCGA are

More information

Development status of OPDIVO (nivolumab) 1

Development status of OPDIVO (nivolumab) 1 November 2, 2018 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy) Approved Approved(EU) Non-small cell

More information

Trial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor

Trial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor Supplemental table 1. Overview of recent clinical phase I and II trials assessing the safety and efficacy of TCR-modified T cells in cancer patients as registered at clinicaltrials.gov by September 1,

More information

Development Pipeline Progress Status. February 1, 2019

Development Pipeline Progress Status. February 1, 2019 Development Pipeline Progress Status February 1, 2019 /9 Development status of OPDIVO (nivolumab) (1) Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy)

More information

MicroRNAs: the primary cause or a determinant of progression in leukemia?

MicroRNAs: the primary cause or a determinant of progression in leukemia? MicroRNAs: the primary cause or a determinant of progression in leukemia? The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation

More information

National Cancer Drugs Fund List - Approved

National Cancer Drugs Fund List - Approved National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer

More information

Tumor Immunology. Tumor (latin) = swelling

Tumor Immunology. Tumor (latin) = swelling Tumor Immunology Tumor (latin) = swelling benign tumor malignant tumor Tumor immunology : the study of the types of antigens that are expressed by tumors how the immune system recognizes and responds to

More information

September 20, Submitted electronically to: Cc: To Whom It May Concern:

September 20, Submitted electronically to: Cc: To Whom It May Concern: History Study (NOT-HL-12-147), p. 1 September 20, 2012 Re: Request for Information (RFI): Building a National Resource to Study Myelodysplastic Syndromes (MDS) The MDS Cohort Natural History Study (NOT-HL-12-147).

More information

Epidemiology in Texas 2006 Annual Report. Cancer

Epidemiology in Texas 2006 Annual Report. Cancer Epidemiology in Texas 2006 Annual Report Cancer Epidemiology in Texas 2006 Annual Report Page 94 Cancer Incidence and Mortality in Texas, 2000-2004 The Texas Department of State Health Services Texas Cancer

More information

Profiles of gene expression & diagnosis/prognosis of cancer. MCs in Advanced Genetics Ainoa Planas Riverola

Profiles of gene expression & diagnosis/prognosis of cancer. MCs in Advanced Genetics Ainoa Planas Riverola Profiles of gene expression & diagnosis/prognosis of cancer MCs in Advanced Genetics Ainoa Planas Riverola Gene expression profiles Gene expression profiling Used in molecular biology, it measures the

More information

Supplementary Materials for

Supplementary Materials for Supplementary Materials for A Clinical Trial for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes Not Eligible for Standard Clinical Trials Table of Contents Content Page Supplementary

More information

Action to Cure Kidney Cancer Campaign to Fund Kidney Cancer Research

Action to Cure Kidney Cancer Campaign to Fund Kidney Cancer Research Action to Cure Kidney Cancer 2016 Campaign to Fund Kidney Cancer Research Kidney Cancer Facts 9 th most common cancer in the U.S. Until recently, 3 rd highest rate of increasing incidence of all cancers

More information

GWAS of HCC Proposed Statistical Approach Mendelian Randomization and Mediation Analysis. Chris Amos Manal Hassan Lewis Roberts Donghui Li

GWAS of HCC Proposed Statistical Approach Mendelian Randomization and Mediation Analysis. Chris Amos Manal Hassan Lewis Roberts Donghui Li GWAS of HCC Proposed Statistical Approach Mendelian Randomization and Mediation Analysis Chris Amos Manal Hassan Lewis Roberts Donghui Li Overall Design of GWAS Study Aim 1 (DISCOVERY PHASE): To genotype

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION Supplementary Information S1 Class I PI3K isoform alterations in cancer Alteration Type Cancer Type Frequency of Alteration Sample Size Range Class IA PIK3CA (p110α) Mutation Endometrial 10.3-53.0% 29-232

More information

BIOLOGY OF CANCER. Definition: Cancer. Why is it Important to Understand the Biology of Cancer? Regulation of the Cell Cycle 2/13/2015

BIOLOGY OF CANCER. Definition: Cancer. Why is it Important to Understand the Biology of Cancer? Regulation of the Cell Cycle 2/13/2015 BIOLOGY OF CANCER Why is it Important to Understand the Biology of Cancer? Cynthia Smith, RN, BA, MSN, AOCN Oncology Clinical Nurse Specialist Harrison Medical Center Definition: Cancer Regulation of the

More information

Potentially preventable cancers among Alaska Native people

Potentially preventable cancers among Alaska Native people Potentially preventable cancers among Alaska Native people Sarah Nash Cancer Surveillance Director, Alaska Native Tumor Registry Diana Redwood, Ellen Provost Alaska Native Epidemiology Center Cancer is

More information

OBTAINING A MENTORED CAREER DEVELOPMENT AWARD: PERSPECTIVES OF A MENTOR, APPLICANT AND REVIEWER

OBTAINING A MENTORED CAREER DEVELOPMENT AWARD: PERSPECTIVES OF A MENTOR, APPLICANT AND REVIEWER OBTAINING A MENTORED CAREER DEVELOPMENT AWARD: PERSPECTIVES OF A MENTOR, APPLICANT AND REVIEWER May 15, Friday 4pm BRIEF AGENDA 1) Carol Mangione, MD MSPH- Introduction 2) Richard Kravitz, MD MSPH- Perspective

More information

Epidemiology, Prevention & Early Detection (Cancer Control) The Cancer Control Continuum. Epidemiology

Epidemiology, Prevention & Early Detection (Cancer Control) The Cancer Control Continuum. Epidemiology Epidemiology, Prevention & Early Detection (Cancer Control) The Cancer Control Continuum Nancy Thompson, MSN, RN, AOCNS Swedish Cancer Institute Prevention Detection Diagnosis Survivorship Treatment Epidemiology

More information

JAK2 V617F analysis. Indication: monitoring of therapy

JAK2 V617F analysis. Indication: monitoring of therapy JAK2 V617F analysis BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created

More information

The Future of Cancer. Lawrence Tsui Global Risk Products Actuary Swiss Reinsurance Company Hong Kong. Session Number: WBR8

The Future of Cancer. Lawrence Tsui Global Risk Products Actuary Swiss Reinsurance Company Hong Kong. Session Number: WBR8 Lawrence Tsui Global Risk Products Actuary Swiss Reinsurance Company Hong Kong Session Number: WBR8 Agenda Cancer the basics Cancer past and present Cancer the future CANCER THE BASICS Cancer the basics

More information

What Math Can Tell You About Cancer

What Math Can Tell You About Cancer What Math Can Tell You About Cancer J. B. University of Hawai i at Mānoa Hofstra University, October 2017 Overview The human body is complicated. Cancer disrupts many normal processes. Mathematical analysis

More information

THE UC SANTA CRUZ GENOMICS INSTITUTE. David Haussler Distinguished Professor, Biomolecular Engineering Scientific Director

THE UC SANTA CRUZ GENOMICS INSTITUTE. David Haussler Distinguished Professor, Biomolecular Engineering Scientific Director THE UC SANTA CRUZ GENOMICS INSTITUTE David Haussler Distinguished Professor, Biomolecular Engineering Scientific Director April 8, 2015 OUR MISSION Unlocking the world s genomic data to accelerate medical

More information

Cancer Epidemiology. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD

Cancer Epidemiology. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD Cancer Epidemiology Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD Fanconi Anemia Adults, February 2011 Outline Epidemiology FA Literature

More information

Maria Halasz CEO

Maria Halasz CEO Australian biotechnology company listed on the ASX (CDY.AX) Midkine company owns novel therapeutic and diagnostic target Extensive scientific validation including 550+ publications Multiple revenue source

More information

2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill

2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill Number of New Cancers Truman Medical Center Hospital Hill Cancer Registry 2015 Statistical Summary Incidence In 2015, Truman Medical Center diagnosed and/or treated 406 new cancer cases. Four patients

More information

REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) AVASTIN (NON-SMALL CELL LUNG CANCER) - Executive Summary Avastin (bevacizumab): Key Metrics in NSCLC Markets 2012

More information

Cancer Awareness Talk ICPAK 2014

Cancer Awareness Talk ICPAK 2014 Cancer Awareness Talk ICPAK 2014 F. Chite Asirwa, MB ChB. MD. MSc. Internist. Medical Oncologist & Hematologist Asst. Professor of Medicine Division of Hematology/Oncology Indiana University Email: fasirwa@iu.edu

More information

Cancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous

Cancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous Session8 Medical Genetics Cancer Genetics J avad Jamshidi F a s a U n i v e r s i t y o f M e d i c a l S c i e n c e s, N o v e m b e r 2 0 1 7 What is Cancer? Uncontrolled growth of cells Not all tumors

More information

How to Begin Your Ministry

How to Begin Your Ministry How to Begin Your Ministry The fact that one out of three is touched by cancer is an alarming statistic. It is highly unusual to have someone who has not been touched by cancer in this day and age. That

More information

PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019

PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019 MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments

More information

Disease Control & Epidemiology Division

Disease Control & Epidemiology Division Disease Control & Epidemiology Division Morbidity and Mortality Report Data 26 and 27 Data was contributed by Luis Castillo, Manuel Sanchez, Keila Castillo, Veronica Cardenas, and Cande Maldonado Report

More information

ARTICLE IN PRESS. Critical Reviews in Oncology/Hematology xxx (2010) xxx xxx

ARTICLE IN PRESS. Critical Reviews in Oncology/Hematology xxx (2010) xxx xxx Critical Reviews in Oncology/Hematology xxx (2010) xxx xxx Circulating micrornas: Association with disease and potential use as biomarkers Glen Reid, Michaela B. Kirschner, Nico van Zandwijk Asbestos Diseases

More information

Macmillan Publications

Macmillan Publications S1 S2 S3 S3 S3 S4 S5 S6 S7 S8 S8 S9 S10 S11 S11 S12 S13 S14 S15 S17 S18 S19 Bladder Cancer: Non-Invasive, Invasive and Advanced Bone Cancer: Primary, Secondary Colon Cancer, Anal Cancer, Rectal Cancer

More information

Epigenetic inactivation of the CpG demethylase TET1 as a DNA

Epigenetic inactivation of the CpG demethylase TET1 as a DNA Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers Lili Li 1, Chen Li 1, Haitao Mao 1, Zhenfang Du 1, Wai Yee Chan 2, Paul Murray 3, Bing Luo 4, Anthony

More information

Insights into NIH Funding of Hydrocephalus Research. Paul Gross Chairman, Hydrocephalus Association

Insights into NIH Funding of Hydrocephalus Research. Paul Gross Chairman, Hydrocephalus Association Insights into NIH Funding of Hydrocephalus Research Paul Gross Chairman, Hydrocephalus Association Public Funding Landscape Totals, Categories, Institutes and Types Trends over time Discussion Method Searched

More information

NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R)

NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R) Item 18-13c NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May 2013 BREAST CANCER MCN: Breast Disease: Breast Document ready to circulate lead to be discussed

More information

Pathology of Hematopoietic and Lymphoid tissue

Pathology of Hematopoietic and Lymphoid tissue CONTENTS Pathology of Hematopoietic and Lymphoid tissue White blood cells and lymph nodes Quantitative disorder of white blood cells Reactive lymphadenopathies Infectious lymphadenitis Tumor metastasis

More information

Ontario s Referral and Listing Criteria for Adult Pancreas-After- Kidney Transplantation

Ontario s Referral and Listing Criteria for Adult Pancreas-After- Kidney Transplantation Ontario s Referral and Listing Criteria for Adult Pancreas-After- Kidney Transplantation Version 2.0 Trillium Gift of Life Network Adult Pancreas-After-Kidney Transplantation Referral & Listing Criteria

More information

ArQule Jefferies Global Healthcare Conference June 2015

ArQule Jefferies Global Healthcare Conference June 2015 ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning

More information

Barbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi

Barbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi Barbara G. Wells, PharmD, FASHP, FCCP, BCPP Dean and Professor School of Pharmacy, The University of Mississippi Oxford, Mississippi Joseph T. DiPiro, PharmD, FCCP Panoz Professor of Pharmacy, College

More information

Development status of OPDIVO (nivolumab) 1

Development status of OPDIVO (nivolumab) 1 August 1, 2018 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy) Filing Approved (US) Non-small cell lung

More information

Summary of Strategic Competitive Analysis and Publication Planning

Summary of Strategic Competitive Analysis and Publication Planning Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing

More information

Dietary Supplement Research Portfolio at the NIH, ,2

Dietary Supplement Research Portfolio at the NIH, ,2 The Journal of Nutrition Commentary Dietary Supplement Research Portfolio at the NIH, 2009 2011 1,2 Mary L. Garcia-Cazarin, 3 * Edwina A. Wambogo, 3 Karen S. Regan, 3,4 and Cindy D. Davis 3 3 Office of

More information

ArQule CorporateUpdate

ArQule CorporateUpdate ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform

More information

Tumour Markers. For these reasons, only a handful of tumour markers are commonly used by most doctors.

Tumour Markers. For these reasons, only a handful of tumour markers are commonly used by most doctors. Tumour Markers What are Tumour Markers? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer

More information

Session 4 Rebecca Poulos

Session 4 Rebecca Poulos The Cancer Genome Atlas (TCGA) & International Cancer Genome Consortium (ICGC) Session 4 Rebecca Poulos Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 20

More information

Neuroscience International Funding Opportunities at NINDS & NIH

Neuroscience International Funding Opportunities at NINDS & NIH Neuroscience International Funding Opportunities at NINDS & NIH Yuan Liu, PhD Chief, Office of International Activities of Neurological Disorders & Stroke (NINDS) s of Health (NIH) U.S.A. July 20, 2007

More information

Merck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017

Merck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017 Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,

More information